News | April 6, 2021

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic Data...

News | March 30, 2021

BrightInsight Announces $101M in Series C Funding led by General Catalyst The Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechSAN JOSE, Calif., March 30, 2021 – BrightInsight, Inc.,...

News | February 3, 2021

Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage...

News | February 1, 2021

Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on...

News| January 7, 2021

ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERING Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

News | January 4, 2021

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS HPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development SOUTH SAN FRANCISCO, Calif., Jan....